Short Peptides Protect Oral Stem Cells from Ageing.

Sinjari B, Diomede F, Khavinson V, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S

Stem cell reviews and reports1 Feb 2020Cited by 18 (Europe PMC)

PMID31677028DOI10.1007/s12015-019-09921-3PepBankPUB-31677028

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In oral stem cells at passage 25, AEDG decreased p16 mRNA expression by 1.56-2.44 times (one range for p16 and p21) versus control.
In plain wordsIn lab-grown oral stem cells, AEDG lowered an ageing marker (p16) compared with untreated cells.
Peptide
Epitalon
Outcome
Decreasep16 mRNA expression
Study
humann: not reported in source
Human periodontal ligament stem cells and gingival mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
p16 mRNA decrease
1.56 to 2.44 times
AEDG vs control
Source sentences
Summary
AEDG peptide decreased p16 and p21 mRNA expression by 1.56-2.44 times in comparison with the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs). Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702801
02LabIn vitro (cells)Activity measurement
In oral stem cells at passage 25, AEDG decreased p21 mRNA expression by 1.56-2.44 times (one range for p16 and p21) versus control.
In plain wordsIn lab-grown oral stem cells, AEDG lowered an ageing marker (p21) compared with untreated cells.
Peptide
Epitalon
Outcome
Decreasep21 mRNA expression
Study
humann: not reported in source
Human periodontal ligament stem cells and gingival mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
p21 mRNA decrease
1.56 to 2.44 times
AEDG vs control
Source sentences
Summary
AEDG peptide decreased p16 and p21 mRNA expression by 1.56-2.44 times in comparison with the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs). Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702802
03LabIn vitro (cells)Mechanism
In oral human mesenchymal stem cells, KED decreased p16 mRNA expression versus control within the reported combined marker range.
In plain wordsIn cells, KED reduced p16 gene expression compared with control.
Peptide
Vesugen (KED)
Outcome
Decreasep16 mRNA expression
Study
humann: not reported in source
oral mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
p16 and p21 mRNA decrease
1.82 to 3.23 times
KED versus control, combined marker range
Source sentences
Summary
KED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs).
Summary · context
Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702803
04LabIn vitro (cells)Mechanism
In oral human mesenchymal stem cells, KED decreased p21 mRNA expression versus control within the reported combined marker range.
In plain wordsIn cells, KED reduced p21 gene expression compared with control.
Peptide
Vesugen (KED)
Outcome
Decreasep21 mRNA expression
Study
humann: not reported in source
oral mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Measurements
p16 and p21 mRNA decrease
1.82 to 3.23 times
KED versus control, combined marker range
Source sentences
Summary
KED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs).
Summary · context
Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702804
05LabIn vitro (cells)Mechanism
In oral human mesenchymal stem cells, immunofluorescence confirmed the reduction of p16 with KED versus control.
In plain wordsIn cells, imaging confirmed reduced p16 with KED compared with control.
Peptide
Vesugen (KED)
Outcome
Decreasep16 immunofluorescence
Study
humann: not reported in source
oral mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Source sentences
Summary
These results were confirmed by immunofluorescent visualization.
4 context sentences(design, population, supporting numbers)
Summary · context
KED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group.
Summary · context
Cell cultures were analyzed by an immunofluorescence method and RT-PCR on the p16 and p21 senescence markers expression.
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs).
Summary · context
Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702805
06LabIn vitro (cells)Mechanism
In oral human mesenchymal stem cells, immunofluorescence confirmed the reduction of p21 with KED versus control.
In plain wordsIn cells, imaging confirmed reduced p21 with KED compared with control.
Peptide
Vesugen (KED)
Outcome
Decreasep21 immunofluorescence
Study
humann: not reported in source
oral mesenchymal stem cells at passage 25
Comparator
Control without peptide
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Source sentences
Summary
These results were confirmed by immunofluorescent visualization.
4 context sentences(design, population, supporting numbers)
Summary · context
KED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group.
Summary · context
Cell cultures were analyzed by an immunofluorescence method and RT-PCR on the p16 and p21 senescence markers expression.
Summary · context
2 types of hMSCs were investigated: human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs).
Summary · context
Cells at the 25th passage were divided into 3 groups: 1 - control (without adding peptide), 2 - treated with AEDG peptide, 3 - treated with KED peptide.
Report a problemFND-3167702806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 10Current
28 Oct 2026, 02:02 UTC
The same notice was added 7 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.